Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial
- PMID: 15883316
- DOI: 10.1212/01.WNL.0000159740.16984.3C
Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial
Abstract
Background: AN1792 (beta-amyloid [Abeta]1-42) immunization reduces Abeta plaque burden and preserves cognitive function in APP transgenic mice. The authors report the results of a phase IIa immunotherapy trial of AN1792(QS-21) in patients with mild to moderate Alzheimer disease (AD) that was interrupted because of meningoencephalitis in 6% of immunized patients.
Methods: This randomized, multicenter, placebo-controlled, double-blind trial of IM AN1792 225 microg plus the adjuvant QS-21 50 microg (300 patients) and saline (72 patients) included patients aged 50 to 85 years with probable AD, Mini-Mental State Examination (MMSE) 15 to 26. Injections were planned for months 0, 1, 3, 6, 9, and 12. Safety and tolerability were evaluated, and pilot efficacy (AD Assessment Scale-Cognitive Subscale [ADAS-Cog], MRI, neuropsychological test battery [NTB], CSF tau, and Abeta42) was assessed in anti-AN1792 antibody responder patients (immunoglobulin G titer > or = 1:2,200).
Results: Following reports of meningoencephalitis (overall 18/300 [6%]), immunization was stopped after one (2 patients), two (274 patients), or three (24 patients) injections. Of the 300 AN1792(QS-21)-treated patients, 59 (19.7%) developed the predetermined antibody response. Double-blind assessments were maintained for 12 months. No significant differences were found between antibody responder and placebo groups for ADAS-Cog, Disability Assessment for Dementia, Clinical Dementia Rating, MMSE, or Clinical Global Impression of Change, but analyses of the z-score composite across the NTB revealed differences favoring antibody responders (0.03 +/- 0.37 vs -0.20 +/- 0.45; p = 0.020). In the small subset of subjects who had CSF examinations, CSF tau was decreased in antibody responders (n = 11) vs placebo subjects (n = 10; p < 0.001).
Conclusion: Although interrupted, this trial provides an indication that Abeta immunotherapy may be useful in Alzheimer disease.
Similar articles
-
Rationale for peptide and DNA based epitope vaccines for Alzheimer's disease immunotherapy.CNS Neurol Disord Drug Targets. 2009 Apr;8(2):128-43. doi: 10.2174/187152709787847298. CNS Neurol Disord Drug Targets. 2009. PMID: 19355933 Free PMC article. Review.
-
Long-term follow-up of patients immunized with AN1792: reduced functional decline in antibody responders.Curr Alzheimer Res. 2009 Apr;6(2):144-51. doi: 10.2174/156720509787602852. Curr Alzheimer Res. 2009. PMID: 19355849 Free PMC article. Clinical Trial.
-
Progress in the active immunotherapeutic approach to Alzheimer's disease: clinical investigations into AN1792-associated meningoencephalitis.Neurodegener Dis. 2008;5(3-4):194-6. doi: 10.1159/000113700. Epub 2008 Mar 6. Neurodegener Dis. 2008. PMID: 18322388 Review.
-
Effects of Abeta immunization (AN1792) on MRI measures of cerebral volume in Alzheimer disease.Neurology. 2005 May 10;64(9):1563-72. doi: 10.1212/01.WNL.0000159743.08996.99. Neurology. 2005. PMID: 15883317 Clinical Trial.
-
Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization.Neurology. 2003 Jul 8;61(1):46-54. doi: 10.1212/01.wnl.0000073623.84147.a8. Neurology. 2003. PMID: 12847155 Clinical Trial.
Cited by
-
Targeting aging and age-related diseases with vaccines.Nat Aging. 2024 Apr;4(4):464-482. doi: 10.1038/s43587-024-00597-0. Epub 2024 Apr 15. Nat Aging. 2024. PMID: 38622408 Review.
-
The association of microbial infection and adaptive immune cell activation in Alzheimer's disease.Discov Immunol. 2023 Sep 26;2(1):kyad015. doi: 10.1093/discim/kyad015. eCollection 2023. Discov Immunol. 2023. PMID: 38567070 Free PMC article. Review.
-
Expression of antimicrobial host defence peptides in the central nervous system during health and disease.Discov Immunol. 2022 Jul 26;1(1):kyac003. doi: 10.1093/discim/kyac003. eCollection 2022. Discov Immunol. 2022. PMID: 38566904 Free PMC article. Review.
-
Recent Advances in Clinical Trials in Multiple System Atrophy.Curr Neurol Neurosci Rep. 2024 Apr;24(4):95-112. doi: 10.1007/s11910-024-01335-0. Epub 2024 Feb 28. Curr Neurol Neurosci Rep. 2024. PMID: 38416311 Review.
-
Lessons Learned from Approval of Aducanumab for Alzheimer's Disease.Annu Rev Med. 2024 Jan 29;75:99-111. doi: 10.1146/annurev-med-051022-043645. Annu Rev Med. 2024. PMID: 38285515 Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical